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Background: We describe trends in characteristics and outcomes among adults initiating HIV care and treatment in
Ethiopia from 2006-2011.
Methods: We conducted a retrospective longitudinal analysis of HIV-positive adults (≥15 years) enrolling at 56
Ethiopian health facilities from 2006–2011. We investigated trends over time in the proportion enrolling through
provider-initiated counseling and testing (PITC), baseline CD4+ cell counts and WHO stage. Additionally, we
assessed outcomes (recorded death, loss to follow-up (LTF), transfer, and total attrition (recorded death plus LTF))
before and after ART initiation. Kaplan-Meier techniques estimated cumulative incidence of these outcomes through
36 months after ART initiation. Factors associated with LTF and death after ART initiation were estimated using
Hazard Ratios accounting for within-clinic correlation.
Results: 93,418 adults enrolled into HIV care; 53,300 (57%) initiated ART. The proportion enrolled through PITC
increased from 27.6% (2006–2007) to 44.8% (2010–2011) (p < .0001). Concurrently, median enrollment CD4+ cell
count increased from 158 to 208 cells/mm3 (p < .0001), and patients initiating ART with advanced WHO stage
decreased from 56.6% (stage III) and 15.0% (IV) in 2006–2007 to 47.6% (stage III) and 8.5% (IV) in 2010–2011. Median
CD4+ cell count at ART initiation remained stable over time. 24% of patients were LTF before ART initiation. Among
those initiating ART, attrition was 30% after 36 months, with most occurring within the first 6 months. Recorded
death after ART initiation was 6.4% and 9.2% at 6 and 36 months, respectively, and decreased over time. Younger
age, male gender, never being married, no formal education, low CD4+ cell count, and advanced WHO stage were
associated with increased LTF. Recorded death was lower among younger adults, females, married individuals,
those with higher CD4+ cell counts and lower WHO stage at ART initiation.
Conclusions: Over time, enrollment in HIV care through outpatient PITC increased and patients enrolled into HIV
care at earlier disease stages across all HIV testing points. However, median CD4+ cell count at ART initiation
remained steady. Pre- and post-ART attrition (particularly in the first 6 months) have remained major challenges in
ensuring prompt ART initiation and retention on ART.
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Ethiopia has experienced a rapid scale up of antiretro-
viral treatment (ART) since 2005, when free ART was
introduced. Following decentralization of HIV services
to health centers beginning in the second half of 2006,
the program has rapidly expanded the provision of ART
services to urban and rural populations throughout the
country. Currently an estimated 800,000 individuals in
Ethiopia are living with HIV [1] and based on the
Ethiopian Demographic and Health survey, the esti-
mated adult (15–59 years) HIV prevalence was 1.5% in
2011 [2]. The number of individuals that ever started
ART increased from about 9,700 at the end of 2004 [3],
to nearly 290,000 by 2012 [4], with an estimated 61% of
individuals eligible for ART receiving treatment [4].
Trends over time and characteristics of the patient
population seeking HIV care in Ethiopia have been
under-reported in the literature compared with higher-
prevalence countries in sub-Saharan Africa. Several
reports have focused on individual hospitals or health
centers in Ethiopia [5-9], using aggregate-level national
reporting data [10-13], or sampling methodologies to
obtain patient-level information on a subset of key out-
comes [14]. However, large-scale multi-regional assess-
ments of the adult population seeking HIV care using
routinely-collected patient-level data in Ethiopia have
not been reported.
Ethiopia is a relatively low HIV prevalence country
which in 2007 embarked on an expansive national pro-
gram of universal HIV counseling and testing [15] where
all individuals attending a clinical setting for any reason
are offered HIV testing as part of routine services, a
unique situation among countries in sub-Saharan Africa.
These guidelines recommended an “opt out” approach
offering HIV testing to all patients accessing health-care.
The effectiveness of the PITC approach in earlier identi-
fication, enrollment in care, and ART initiation of HIV
positive patients has not been examined in Ethiopia.
This approach differs from Voluntary Counseling and
Testing, where individuals attend clinic specifically to re-
ceive an HIV test. Furthermore, despite successes in roll-
ing out a large scale ART program, significant hurdles
remain in starting all ART-eligible patients on treatment
and in retaining them in care [12]. Late ART initiation
despite eligibility and high rates of loss to follow-up
(LTF) among patients after enrollment into care com-
promise the benefits to be gained from care and treat-
ment programs [3,10-13]. While death rates remain high
among patients initiating ART at advanced stages of dis-
ease, information on death and trends over time among
patients in pre-ART care and those on ART is lacking.
In the present analysis, we aim to describe trends over
time in enrollment of adults identified through PITC vs.
VCT testing approaches, key demographic and clinicaltrends at enrollment into HIV care and at ART initi-
ation, as well as outcomes after enrollment in care and
ART initiation.
Methods
Study design and study population
We conducted an observational longitudinal analysis
using routinely-collected clinical information on HIV-
infected adults enrolled at 56 health facilities from 4 re-
gions (Oromia, Dire Dawa, Harari, and Somali) in
Ethiopia. These health facilities collected longitudinal
electronic patient-level clinical information as part of
routine care provision which were de-identified and in-
cluded in the Optimal Models of HIV Care study. Data
collection procedures for the Optimal Models study have
been described elsewhere [16]. ICAP at Columbia Uni-
versity (ICAP) is an implementing partner supporting
HIV care and treatment services in Ethiopia under fund-
ing from the President’s Emergency Plan for AIDS Relief
(PEPFAR) through the US Centers for Disease Control
and Prevention (CDC). At the end of 2011, ICAP was
providing technical assistance to 86 hospitals and health
centers, including 56 with electronic patient-level data
that are included in this analysis. These 56 sites consti-
tute approximately 90% of the data of all adults enrolled
in HIV care at ICAP supported health facilities during
the 2006-2011time period.
Information on all adult patients (≥15 years of age) en-
rolled in care between January 1, 2006 and December
31, 2011 were included in this analysis. Information on
follow-up visits was included through December 31,
2012. CD4+ cell counts at enrollment into HIV care and
ART initiation were taken as the most recent CD4+ cell
count recorded within 3 months prior to one month
after enrollment or ART initiation. Patient information
routinely collected during each clinic visit was docu-
mented by health care providers on national patient
forms and subsequently entered by trained data clerks
into a patient-level database developed by ICAP. Data
quality assessment was conducted quarterly to check
completeness and accuracy. De-identified versions of
electronic databases were compiled semi-annually by
ICAP database managers and shared with study investi-
gators at ICAP.
Statistical methods
Descriptive statistics are presented on demographic and
clinical characteristics of the study population overall,
and stratified by year of enrollment into HIV care and,
for those starting treatment, year of ART initiation. CD4+
cell count at enrollment and ART initiation were identi-
fied within a window period of three months prior, to one
month after enrollment or ART initiation, respectively.
Chi-square tests for group difference are presented for
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ables hypothesized a priori to change over time as a result
of PITC scale-up (WHO stage and CD4+ cell count at en-
rollment into care/ART initiation, PITC and VCT point of
entry) CD4 were tested for trends over time using univari-
ate linear mixed models (ordinal outcomes for WHO
stage and CD4 categories; binomial outcome for PITC
and VCT) with a random effect to account for with-site
correlations.
Outcomes of patients in pre-ART care (pre-ART
outcomes) were classified into the following mutually
exclusive categories twelve months after enrollment:
(1) initiating ART, (2) remaining in pre-ART care but
not initiating ART, (3) transferring to another clinic
before initiating ART, (4) recorded as dying before
ART initiation, and (5) LTF before ART initiation. Pa-
tients were considered LTF before ART initiation if
they were not recorded as dead, transferred, or initiat-
ing ART, and if they did not have a recorded visit for
12 months or more with no subsequent visit recorded
in the database. Patients LTF were censored based on
their date of last visit. We further divided patients LTF
before ART initiation into those lost after only one
(enrollment) visit and those lost after two or more
pre-ART visits. Among patients ever initiating ART,
we estimated the cumulative incidence of recorded
death, LTF, and total attrition (recorded death or LTF)
using Kaplan-Meier survival analysis. Patients were
considered LTF after ART initiation when they were
not recorded as dead or transferred, and if they did
not have a recorded visit for 6 months or more.
Individual-level factors associated with reported LTF
and death after ART initiation were estimated using
Cox Proportional Hazards models with robust sand-
wich estimates to account for within-clinic correlation.
Covariates included in the model were a priori hy-
pothesized to influence recorded death or LTF, and in-
clude: age, sex, religion, marital status, education
level, WHO stage at ART initiation, CD4+ cell count
at ART initiation, ART regimen, whether an individual
switched regimens during follow-up, point of HIV
testing (PITC, VCT, other hospitals/health centers,
community referral, unknown/missing), facility type
(primary vs. secondary/tertiary), location (urban, semi-
urban, rural), and whether on-site CD4+ testing was
provided. For analyses with recorded death as the out-
come of interest, patients transferring to another facil-
ity or lost to follow-up were censored according to
their date of last contact with the facility. For analyses
with LTF as the outcome of interest, patients accrued
follow-up time until a date of recorded death, transfer,
LTF, or the end of the study follow-up period. Sensi-
tivity analyses examined whether treating recorded
death as a competing risk for LTF appreciably changedthe results using methods for calculating a sub-
distribution hazard outlined by Fine and Grey [17].
Ethical approval
Use of anonymized patient-level data from health facil-
ities was conducted as part of the Identifying Optimal
Models of HIV Care and Treatment study protocol. All
data were de-identified prior to analysis and the investi-
gators had no access to identifiable patient information.
Institutional Review Board (IRB) approval was obtained
from the National Research Ethics Review Committee in
Ethiopia; the study was designated non-human subjects
research by the IRB Columbia University and the Center
for Global Health at the US Centers for Disease Control
and Prevention (CGH/CDC).
Results
Setting and patient characteristics at enrollment in care
A total of 93,418 adults (≥15 years of age) enrolled in
HIV care at one of 56 health facilities were included in
the analysis. Table 1 presents baseline characteristics of
this population, stratified by year of enrollment. Twenty-
five facilities (45%) were in urban, 21 (37%) in semi-urban
and 10 (18%) in rural settings; 32 (57%) were regional
public hospitals. Overall, 53,300 (57%) adults enrolled into
HIV care eventually initiated ART.
Over 60% of the patient population was female. Most
patients reported receiving either no formal education
(29.5%) or education only up to the primary level
(36.6%). Nearly two thirds (61%) of the patients were
25–39 years of age at enrollment with small changes in
age distribution observed over time. Over half of the pa-
tients (52%) were married or living with their partners/
spouses and 61% identified themselves as Orthodox
Christian.
Nearly one-third (31%) of the patients enrolling in HIV
care were referred from VCT testing points, 37% after be-
ing tested through PITC at inpatient, outpatient, tubercu-
losis clinics, and PMTCT points of service, 14% were
tested at another hospital or health center, 1% through
community-based testing and 17% had incomplete infor-
mation on point of testing. The proportion of patients en-
rolled after testing at service points providing PITC
increased substantially from 27.6% in 2006–2007 to 44.8
in 2010–2011 (p <0.0001 for trend over time), while the
proportion identified through VCT declined from 38.1%
in 2006–2007 to 26.4% in 2010–2011 (p <0.0001).
80,102 (86%) of patients had a recorded WHO stage at
enrollment (24,979 (26%) stage I, 16,595 (18%) stage II,
33,072 (35%) stage III, 6,456 (7%) stage IV, and 13,316
(14%) without a recorded WHO stage). The proportion
of patients enrolling with WHO stage III and IV de-
creased over time from 39% (stage III) and 10% (stage
IV) in 2006–2007 to 33% (stage III) and 5% (stage IV) in
Table 1 Adult patient characteristics at enrollment into HIV Care, by enrollment year
Total 2006-2007 2008-2009 2010-2011
p-value1
n = 93,418 %2 n = 34,528 %2 n = 35,242 %2 n = 23,648 %2
Age category <0.0001
15-24 yrs 14,997 16.1 5,361 15.5 5,687 16.1 3,949 16.7
25-39 yrs 57,160 61.2 21,519 62.3 21,532 61.1 14,109 59.7
40-49 yrs 14,675 15.7 5,490 15.
9
5,438 15.4 3,747 15.8
50+ yrs 6,586 7.1 2,158 6.3 2,585 7.3 1,843 7.8
Sex 0.0002
Male 36,906 39.5 13,917 40.3 13,857 39.3 9,132 38.6
Female 56,512 60.5 20,611 59.7 21,385 60.7 14,516 61.4
Religion <0.0001
Orthodox 56,616 60.6 21,398 62.0 21,260 60.3 13,958 59.0
Muslim 16,145 17.3 5,142 14.9 6,157 17.5 4,846 20.5
Protestant 14,205 15.2 5,538 16.0 5,358 15.2 3,309 14.0
Other/Unknown 6,452 6.9 2,450 6.8 2,467 6.6 1,535 6.1
Marital status <0.0001
Never Married 12,591 13.5 4,828 14.0 4,520 12.8 3,243 13.7
Married/Living together 48,218 51.6 16,780 48.6 18,653 52.9 12,785 54.1
Separated/Divorced 16,971 18.2 6,360 18.4 6,289 17.9 4,322 18.3
Widowed 11,165 12.0 4,633 13.4 3,996 11.3 2,536 10.7
Other/Unknown 4,473 4.8 1,927 5.6 1,784 5.1 762 3.2
Education <0.0001
No Education 27,547 29.5 9,309 27.0 10,697 30.4 7,541 31.9
Primary 34,178 36.6 12,768 37.0 12,794 36.3 8,616 36.4
Secondary 20,943 22.4 8,667 25.1 7,603 21.6 4,673 19.8
Tertiary 5,565 6.0 1,606 4.7 2,118 6.0 1,841 7.8
Other/Unknown 5,185 5.6 2,178 6.3 2,030 5.8 977 4.1
Point of entry into care <0.0001
PITC 34,566 37.0 9,538 27.6 14,425 40.9 10,603 44.8
VCT 29,128 31.2 13,162 38.1 9,713 27.6 6,253 26.4
Other Hospital/HC 12,930 13.8 6,418 18.6 4,142 11.8 2,370 10.0
Community 1,143 1.2 483 1.4 370 1.0 290 1.2
Unknown/missing 15,651 16.8 4,927 14.3 6,592 18.7 4,132 17.5
Transferred in 1,607 1.7 526 1.5 535 1.5 546 2.3 <0.0001
WHO Stage <0.0001
Stage I 23,979 26 6,891 20 9,767 28 7,321 31
Stage II 16,595 18 5,272 15 6,655 19 4,668 20
Stage III 33,072 35 13,299 39 12,023 34 7,750 33
Stage IV 6,456 7 3,395 10 1,800 5 1,261 5
Missing 13,316 14 5,671 16 4,997 14 2,648 11
CD4+ cell count (cells/mm3)
Median(IQR) 183 (87–342) 158 (76–293) 195 (93–360) 208 (98–376) <0.0001
<100 19,392 21 8,017 23 6,814 19 4,561 19
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100-199 16,818 18 6,557 19 6,087 17 4,174 18
200-350 15,077 16 5,006 14 5,809 16 4,262 18
350+ 16,364 18 4,612 13 6,650 19 5,102 22
Missing 25,767 28 10,336 30 9,882 28 5,549 23
TB screening at enrollment <0.0001
Yes 54,033 57.8 11,275 32.7 23,505 66.7 19,253 81.4
No/not recorded 39,385 42.2 23,253 67.3 11,737 33.3 4,395 18.6
TB treatment at enrollment <0.0001
Yes 8,445 9.0 3,091 9.0 2,969 8.4 2,385 10.1
No/not recorded 84,973 91.0 31,437 91.0 32,273 91.6 21,263 89.9
Cotrimoxazole at enrollment <0.0001
Yes 59,652 63.9 20,032 58.0 22,870 64.9 16,750 70.8
No/not recorded 33,766 36.1 14,496 42.0 12,372 35.1 6,898 29.2
Facility type <0.0001
Primary (11 sites) 4,844 5.2 1,316 3.8 1,934 5.5 1,594 6.7
Secondary/tertiary (45 sites) 88,574 94.8 33,212 96.2 33,308 94.5 22,054 93.3
Setting <0.0001
Urban city (25 sites) 57,904 62.0 22,693 65.7 21,408 60.7 13,803 58.4
Semi-urban (21 sites) 29,219 31.3 10,492 30.4 11,442 32.5 7,285 30.8
Rural (10 sites) 6,295 6.7 1,343 3.9 2,392 6.8 2,560 10.8
Initiated ART
Yes 53,300 57.1 21,920 63.5 19,296 54.8 12,084 51.1 <0.0001
No 40,118 42.9 12,608 36.5 15,946 45.2 11,564 48.9
1p-values based on chi-squared test for any difference across groups over time. see text for specific tests for trend.
2categorical percentages may not total exactly 100% due to roundoff errors.
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had a recorded CD4+ cell count at enrollment while
25,767 (28%) were missing enrollment CD4+ results.
Among those with a recorded enrollment CD4+ cell
count, the median (IQR) cell count was 183 (87–342)
cells/mm3. The median CD4+ cell count increased over
time from 158 (76–293) cells/mm3 in 2006–2007 to 208
(98–376) cells/mm3 in 2010–2011 (p <0.0001 for trend).
The proportion of patients enrolling in care with CD4+
cell count ≥350 cells/mm3 increased from 13% in 2006–
2007 to 22% in 2010–2011 (p < 0.0001 for trend). In-
creases in median CD4+ cell count at enrollment were
observed across all points of entry. Among patients re-
ferred from VCT, median (IQR) CD4+ cell count in-
creased from 173 (86–319) cells/mm3 in 2006–2007 to
244 (120–425 cells/mm3) in 2010–2011. The increase in
median CD4+ cell count at enrollment over time was
smaller for other points of entry (PITC: 148 (70–205)
cells/mm3 in 2006–2007, 187 (86–349) cells/mm3 in
2010–2011; Other hospitals/health centers: 143 (68–
256) cells/mm3 in 2006–2007, 201 (94–360) cells/mm3
in 2010–2011; Community testing: 182 (94–355) cells/
mm3 in 2006–2007, 271 (142–463) cells/mm3 in 2010–2011; Unknown/missing point of entry: 154 (69–291)
cells/mm3 in 2006–2007, 211 (97–375) cells/mm3 in
2010–2011. Similarly, the percentage with WHO stage
III/IV decreased over time for VCT (46.8% (2006–2007)
to 31.3% (2010–2011), PITC (50.4% (2006–2007) to
44.1% (2010–2011), Other hospitals/health centers
(53.2% (2006–2007) to 42.3% (2010–2011) and Un-
known/missing point of testing (42.2% (2006–2007) to
30.2% (2010–2011), while it marginally increased for
Community testing (46.4% (2006–2007) to 49.3% (2010–
2011).Patient characteristics at ART initiation
Overall, 53,300 (57%) patients enrolled in care initi-
ated ART during the period of observation. Table 2
presents patient characteristics at ART initiation. Pa-
tients initiating ART with WHO stage III or IV de-
creased from 56.6% (stage III) and 15% (stage IV) in
2006–2007 to 47.6% (stage III) and 8.5% (stage IV) in
2010–2011 (p <0.0001 for trend). Among the 48,587
(91%) patients initiating ART with a recorded CD4+
cell count at ART initiation, median (IQR) CD4+ cell
Table 2 Adult patient characteristics at ART initiation, by enrollment year
Total 2006-2007 2008-2009 2010-2011
p-value1
n = 53,300 %2 n = 21,920 %2 n = 19,296 %2 n = 12,084 %2
Age category <0.0001
15-24 yrs 6,040 11.3 2425 11.1 2191 11.4 1,424 11.8
25-39 yrs 33,303 62.5 13901 63.4 12031 62.4 7,371 61.0
40-49 yrs 9,722 18.2 4045 18.5 3453 17.9 2,224 18.4
50+ yrs 4,235 8.0 1549 7.1 1621 8.4 1,065 8.8
Sex 0.14
Male 22,302 41.8 9284 42.4 8004 41.5 5,014 41.5
Female 30,998 58.2 12636 57.7 11292 58.5 7,070 58.5
WHO Stage at ART initiation <0.0001
Stage I 7,516 14.1 1830 8.3 3246 16.8 2,440 20.2
Stage II 10,890 20.4 4002 18.3 4297 22.3 2,591 21.4
Stage III 27,930 52.4 12403 56.6 9769 50.6 5,758 47.6
Stage IV 5,894 11.1 3284 15.0 1580 8.2 1,030 8.5
Missing 1,070 2.0 401 1.8 404 2.1 265 2.2
CD4+ cell count, cells/mm3 at ART initiation
Median (IQR) 132 (68–197) 128 (66–192) 137 (71–201) 132 (65–202) <0.0001
<100 18,227 34.2 7,816 35.7 6,247 32.4 4,164 34.5
100-199 18,596 34.9 7,927 36.2 6,696 34.7 3,973 32.9
200-350 10,829 20.3 4,063 18.5 4,121 21.4 2,645 21.9
350+ 935 1.8 409 1.9 309 1.6 217 1.8
Missing 4,713 8.8 1,705 7.8 1,923 10.0 1,085 9.0
First ART regimen <0.0001
D4T-containing regimen 27,380 51.4 15,318 69.9 11,100 57.5 962 8.0
AZT-containing regimen 13,509 25.4 5,733 26.2 5,159 26.7 2,617 21.7
TDF-containing regimen 12,124 22.8 846 3.9 2,840 14.7 8,438 69.8
Other 287 0.5 23 0.1 197 1.0 67 0.6
Facility type <0.0001
Primary (11 sites) 2,421 4.5 712 3.3 906 4.7 803 6.7
Secondary/Tertiary (45 sites) 50,879 95.5 21,208 96.8 18,390 95.3 11,281 93.4
Setting
Urban city (25 sites) 33,491 62.8 14,498 66.1 11,705 60.7 7,288 60.3 <0.0001
Semi-urban (21 sites) 16,711 31.4 6,616 30.2 6,435 33.4 3,660 30.3
Rural (10 sites) 3,098 5.8 806 3.7 1,156 6.0 1,136 9.4
CD4 testing performed on-site
Yes 44,353 83.2 18,699 85.3 15,889 82.3 9,765 80.8 <0.0001
No 8,947 16.8 3,221 14.7 3,407 17.7 2,319 19.2
1p-values based on chi-squared test for any difference across groups over time. see text for specific tests for trend.
2 categorical percentages may not total exactly 100% due to roundoff errors.
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stable over time.
Table 2 also highlights changes in the recommended
first-line ART regimens over time, with stavudine
(D4T)-containing regimens being replaced with tenovo-
fir (TDF) in 2010. D4T-containing regimens (D4T/lamivudine(3TC)/nevirapine(NVP) or D4T/3TC/efavir-
enz(EFV) comprised 57.5% of the first ART regimens in
2008–2009, but only 8% in 2010–2011. Concurrently,
use of TDF-containing regimens (TDF/3TC/NVP or
TDF/3TC/EFV) rose from 14.7% in 2008–2009 to 69.8%
in 2010–2011 (p <0.0001).
Melaku et al. BMC Public Health  (2015) 15:462 Page 7 of 13Outcomes of patients one year after enrollment in HIV
care
Figure 1 presents outcomes one year after enrollment
into HIV care, and the subset of those initiating ART.
Among all patients, 46,972 (50%) initiated ART within
one year of enrollment. Among those not initiating ART
within 1 year of enrollment, 13,869 (30%) did not initiate
ART despite being ART eligible. 19,105 (21%) were
retained in pre-ART care one year after enrollment,
3,831 (4%) transferred to another clinic before ART initi-
ation, 965 (1%) were recorded deaths before ART initi-
ation, and 22,545 (24%) became LTF before ART
initiation. Among the 22,545 LTF, 9,219 (40.9%) were
LTF after attending clinic for only the enrollment visit,
while the remaining 13,326 (59.1%) were LTF after one
or more follow-up visits. Among the 46,972 initiating
ART within one year of enrollment into care, the major-
ity (68%) initiated within 30 days. An additional 16% ini-
tiated within 3 months, 8% within 6 months, and 8%
between 6 and 12 months after enrollment.
Outcomes of patients after ART initiation
Figure 2 presents cumulative incidence of recorded
deaths, LTF, and total attrition (LTF and recorded death)
through 6, 12, 24, and 36 months after ART initiation.
Overall, total attrition was 17% after 6 months, 22% after
12 months, 27% after 24 months, and 30% after
36 months. LTF was 11% at 6 months, 16% at 12 months,
21% at 24 months and 23% at 36 months indicating that
nearly half of patients LTF after ART initiation were lost
within in the first six months. Recorded death was 6% at
6 months, 7% at 12 months, 8% at 24 months, and 9% at
36 months, suggesting that approximately two-thirds of
reported deaths after ART initiation occurred in the first
6 months.Figure 1 Patient outcomes 1 year after enrollment into HIV care (N = 93,41Cumulative incidence of recorded death (Figure 3a.1-
a.3) and LTF (Figure 3b.1-b.3) after ART initiation are
shown stratified by age (Figure 3a.1 and b.1), sex
(Figure 3a.2 and b.2), and year of ART initiation
(Figure 3c.1 and c.2). Young adults 15–24 years of age at
ART initiation experienced lower cumulative incidence
of recorded death (Figure 3a.1) but higher LTF
(Figure 3b.1) than older age groups. Stratified by gender,
males experienced higher recorded death and LTF after
ART initiation compared with females. Cumulative inci-
dence of recorded death decreased over time with adults
initiating ART in 2006–2007 experiencing higher re-
corded deaths after ART initiation than adults initiating
ART in 2010–2011. Loss to follow-up after ART initi-
ation was slightly higher among patients initiating ART
in 2010–2011 compared to patients initiating in 2006–
2009.
Finally, we investigated individual-level factors associ-
ated with reported LTF and death after ART initiation
(Table 3). Youth 15–24 years of age had the highest rates
of LTF (aHR (50+ vs. 15–24): 0.67, 95% CI: 0.54-0.81;
(40–49 vs. 15–24): 0.67, 95% CI: 0.60-0.75; (25–39 vs.
15–24): 0.77, 95% CI: 0.72-0.83), while adults 50 years
and older had the highest rate of recorded death (aHR
1.61, 95% CI: 1.42-1.83; reference group = 15–24 years of
age). Females had lower rates of LTF (aHR 0.73, 95% CI:
0.70-0.76) and slightly lower recorded death rates (aHR
0.90, 95% CI: 0.82-0.98) compared to males. Married in-
dividuals had the lowest rates of LTF and recorded
deaths, and individuals reporting no formal education
had higher LTF rates, but lower recorded death rates,
compared to those reporting some education. Both LTF
and recorded death were highest among individuals with
WHO stage IV and those with CD4+ cell count <100
cells/mm3 at ART initiation. LTF increased with year of8).
Figure 2 Cumulative incidence of recorded death, loss to follow-up, and total attrition (LTF or recorded death) after ART initiation, by time of
event after ART initiation.
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CI:1.15-1.40), while recorded death decreased (201011 vs
2006-07 aHR 0.62, 95% CI: 0.50-0.75). Individuals
referred from PITC (aHR 1.25, 95% CI: 1.20-1.31),
other hospitals/health centers (aHR 1.12, 95% CI: 1.05-
1.20), Community testing (aHR 1.18, 95% CI: 1.06-1.30)
and Unknown/missing (aHR 1.10, 95% CI: 1.01-1.19)
points of entry experienced higher LTF compared to
those enrolling from VCT. Compared to VCT, recorded
death after ART initiation was similar among patients
enrolled from PITC (aHR 1.05, 95% CI: 0.92-1.19),
Community testing (aHR 0.59, 95% CI: 0.30-1.14),
slightly higher for Unknown/missing point of testing
(aHR 1.14, 95% CI: 1.05-1.24) and slightly lower for
other hospitals/health centers (aHR 0.83, 95% CI: 0.72-
0.95).
Among facility-level characteristics considered (facility
type, location, and availability of on-site CD4 testing),
patients initiating ART in rural settings experienced less
LTF compared to patients in urban settings (aHR 0.71,
95% CI: 0.54-0.95), with no observed difference in re-
corded death rates (aHR (semi-urban vs urban): 1.33
(0.91-1.93); rural vs urban: 0.86 (0.66-1.12).
In a sensitivity analysis examining whether treating re-
corded death as a competing risk for LTF appreciably al-
tered our findings, the sub-distribution hazard competing
risk model changed coefficients by an average of > 3%,
suggesting trivial bias in censoring recorded deaths.Discussion
This analysis is the most comprehensive assessment to
date of characteristics of the adult population enrolling
in HIV care at PEPFAR-supported health facilities in
Ethiopia during the period of ART scale-up and adop-
tion of the opt out PITC approach. Ethiopia’s experience
is unique in that it scaled up PITC in a low-prevalence
setting without expanding guidelines for ART eligibility.
In our analysis, we observed a substantial increase in the
proportion of adults enrolling in HIV care after testing
HIV-positive through PITC services (from 27.6% in
2006–2007 to 44.8% in 2010–2011). Routine HIV testing
has been suggested to increase early diagnosis of HIV
and improve access to HIV care [18], but other investi-
gations have concluded that PITC is more likely to inci-
dentally identify later-stage HIV positive individuals who
have not previously sought out an HIV test through
VCT [19]. In this analysis, increases in average CD4+
cell count, and lower average WHO stage, at enrollment
into HIV care were observed over time across all points
of testing, although the smallest increase occurred
among those testing through PITC. Temporal trends to-
ward increasing average CD4+ cell count, and decreas-
ing average WHO stage, at enrollment have been
observed elsewhere [20].
Enrollment of patients into HIV care at earlier disease
stages seems to have reduced somewhat the proportion of
those initiating ART with WHO stage III or IV disease.
Figure 3 Cumulative incidence of recorded death (Figure a.1-a.3) and loss to follow-up (Figure b.1-b.3) after ART initiation. Figure a.1 and b.1:
stratified by age at ART initiation. Figure a.2 and b.2: stratified by gender. Figure a.3 and b.3: stratified by year of ART initiation.
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remained stable over time. This, coupled with unchanged
guidelines based on WHO 2006 recommendations for
ART initiation (CD4 cell count ≤ 200 cells/mm3) in
Ethiopia during the time period covered [21], suggests that
identification of HIV positive patients at an earlier stage in
disease progression will not guarantee earlier ART initi-
ation. Countries which have expanded guidelines for ART
initiation have seen modest increases in median CD4+ cellcounts at ART initiation over time [22]. Ethiopia has re-
cently adopted WHO 2013 guidelines for initiating pa-
tients with a CD4+ cell count < 500 cells/mm3 and future
analyses can investigate the impact of guideline switching
on median CD4+ cell counts at ART initiation.
Nearly a quarter of adults enrolling into HIV care were
LTF before ART initiation. This finding is similar to re-
sults reported by Mulissa et al. from one hospital in
Ethiopia [7], and lower than estimates from a multi-
Table 3 Hazard ratio of LTF and death after ART initiation
LTF Recorded death
Crude Adjusted Crude Adjusted
HR1 95% CI aHR1,2 95% CI HR1 95% CI aHR1,2 95% CI
Age category
15-24 yrs 1 reference 1 reference 1 reference 1 reference
25-39 yrs 0.78 0.72-0.85 0.77 0.72-0.83 1.2 1.10-1.30 1.11 1.02-1.21
40-49 yrs 0.70 0.62-0.79 0.67 0.60-0.75 1.39 1.25-1.55 1.30 1.14-1.48
50+ yrs 0.74 0.60-0.91 0.67 0.54-0.81 1.54 1.38-1.73 1.61 1.42-1.83
Sex
Male 1 reference 1 reference 1 reference 1 reference
Female 0.79 0.75-0.83 0.73 0.70-0.76 0.71 0.66-0.77 0.90 0.82-0.98
Religion
Orthodox 1 reference 1 reference 1 reference 1 reference
Muslim 1.22 1.00-1.48 1.17 1.01-1.35 1.03 0.89-1.19 0.98 0.86-1.13
Protestant 0.89 0.72-1.11 0.99 0.88-1.10 0.84 0.70-1.00 0.77 0.69-0.86
Other/Unknown 1.20 1.01-1.43 0.91 0.80-1.03 1.15 0.87-1.53 0.88 0.70-1.10
Marital status
Never Married 1 reference 1 reference 1 reference 1 reference
Married/Living together 0.63 0.58-0.67 0.67 0.63-0.71 0.8 0.68-0.95 0.84 0.75-0.95
Separated/Divorced 0.83 0.77-0.89 0.90 0.84-0.96 0.92 0.78-1.09 1.02 0.87-1.19
Widowed 0.68 0.63-0.73 0.78 0.71-0.86 0.76 0.66-0.88 0.92 0.79-1.06
Other/Unknown 1.04 0.78-1.39 0.97 0.80-1.03 1.12 0.73-1.72 1.08 0.88-1.33
Education
No Education 1 reference 1 reference 1 reference 1 reference
Primary 0.74 0.70-0.79 0.71 0.66-0.75 1.23 1.16-1.29 1.27 1.18-1.36
Secondary 0.64 0.58-0.71 0.59 0.53-0.66 1.47 1.33-1.62 1.51 1.38-1.66
Tertiary 0.53 0.47-0.59 0.48 0.42-0.55 1.43 1.24-1.66 1.57 1.38-177
Other/Unknown 1.04 0.80-1.36 0.96 0.79-1.17 1.60 1.16-2.23 1.36 1.05-1.75
WHO Stage at ART initiation
Stage I 1 reference 1 reference 1 reference 1 reference
Stage II 0.96 0.86-1.07 0.94 0.85-1.04 1.15 0.96-1.38 1.07 0.89-1.27
Stage III 1.30 1.15-1.47 1.19 1.07-1.32 2.06 1.70-2.49 1.68 1.41-1.99
Stage IV 1.80 1.48-2.18 1.60 1.38-1.85 4.25 3.26-5.52 2.98 2.32-3.84
Missing 1.28 1.12-1.47 1.18 1.07-1.33 2.3 1.69-3.11 1.66 1.22-2.24
CD4+ cell count (cells/mm3) at ART initiation
<100 1.39 1.18-1.64 1.43 1.20-1.71 1.62 1.27-2.06 1.84 1.37-2.46
100-199 0.97 0.82-1.16 1.09 0.91-1.31 0.75 0.57-0.98 1.01 0.74-1.37
200-350 0.87 0.72-1.04 0.96 0.78-1.19 0.48 0.37-0.62 0.64 0.49-0.85
350+ 1 reference 1 reference 1 reference 1 reference
Missing 1.36 1.09-1.70 1.46 1.20-1.77 1.67 1.26-2.21 1.81 1.36-2.41
First ART regimen
D4T-containing regimen 1 reference 1 reference 1 reference 1 reference
AZT-containing regimen 0.86 0.75-0.98 0.76 0.67-0.85 0.75 0.64-0.88 0.79 0.69-0.91
TDF-containing regimen 0.92 0.81-1.04 0.66 0.59-0.74 0.60 0.51-0.70 0.74 0.64-0.86
Other 2.91 2.08-3.78 2.72 2.07-3.58 1.35 0.79-2.30 1.51 0.81-2.81
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Table 3 Hazard ratio of LTF and death after ART initiation (Continued)
Change of ART regimen 0.26 0.21-0.32 0.25 0.19-0.31 0.48 0.42-0.56 0.41 0.35-0.49
Enrollment year
2006-2007 1 reference 1 reference 1 reference 1 reference
2008-2009 1.05 0.96-1.14 1.05 0.95-1.14 0.58 0.49-0.69 0.69 0.60-0.78
2010-2011 1.15 1.00-1.33 1.27 1.15-1.40 0.67 0.62-0.74 0.62 0.50-0.75
Point of entry
PITC 1.33 1.24-1.41 1.25 1.20-1.31 1.19 1.05-1.35 1.05 0.92-1.19
VCT 1 reference 1 reference 1 reference
Other Hospital/HC 1.19 1.08-1.30 1.12 1.05-1.20 0.89 0.78-1.03 0.83 0.72-0.95
Community 1.42 1.23-1.63 1.18 1.06-1.30 0.56 0.24-1.31 0.59 0.30-1.14
Unknown/missing 1.20 1.07-1.34 1.10 1.01-1.19 1.08 0.90-1.30 1.14 1.05-1.24
Facility type
Primary 0.67 0.49-0.92 0.86 0.60-1.24 1.03 0.63-1.69 1.28 0.77-2.14
Secondary/tertiary 1 reference 1 reference 1 reference 1 reference
Setting
Urban city (25 sites) 1 reference 1 reference 1 reference 1 reference
Semi-urban (21 sites) 0.93 0.71-1.21 0.89 0.72-1.09 1.33 0.87-2.05 1.36 0.86-2.16
Rural(10 sites) 0.67 0.49-0.92 0.66 0.51-0.85 2.06 1.35-3.16 1.92 1.16-3.18
CD4 testing on-site 1.47 1.18-1.83 1.31 1.08-1.60 0.68 0.48-0.96 0.85 0.62-1.06
1Hazard ratios estimated using robust sandwich estimators for variance to account for within-clinic correlation.
2Adjusted for other variables in table.
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Tanzania [23] and from a sub-district in KwaZulu-Natal,
South Africa [24]. Reasons for LTF before ART initiation
are myriad but likely include lack of documentation of
transfers and deaths along with true disengagement from
care. In our study, LTF was higher among males than fe-
males, which is similar to reports from other settings
[25]. Pre-ART retention is important to optimize health
outcomes as it enables patients to be consistently moni-
tored and promptly initiated on ART when eligible. The
high attrition before ART initiation in this population,
while lower than observed in other settings, highlights
an important area of potential intervention in the HIV
care cascade. Better patient tracing procedures, better
understanding of loss to follow-up and earlier initiation
of ART to reduce mortality have been recommended to
improve retention [26-28].
After ART initiation, most attrition occurred within
6 months, suggesting that the initial time period after a
patient initiates ART may be the most critical point in
which to focus efforts aimed at improving retention.
Early patient losses have also been reported from other
cohorts [29,30]. With a better understanding of the rea-
sons for LTF after ART initiation, interventions can be
designed that improve treatment retention and ultim-
ately, patient outcomes.
Twelve-month recorded mortality after ART initiation
was 7.4% in our population. This is similar to a study fromMozambique using routinely-collected service delivery
data [31], and somewhat lower than reported from other
countries in sub-Saharan Africa [32]. Our measure of re-
corded mortality is an underestimate of the true mortality
as we did not actively ascertain death records. LTF is com-
prised of individuals truly defaulting from care, in addition
to undocumented transfers and unascertained deaths. We
expect that a large but unknown proportion of the pa-
tients classified as LTF (16% at 12 months among adults
initiating ART in our analysis) were actually unascertained
deaths, and our analysis found that markers of poor im-
munologic health at ART initiation (low CD4+ cell count
and WHO stage III/IV) were associated with increased
hazard of LTF. For example, if we were to assume that ap-
proximately 33% of the patients LTF were actually unre-
ported deaths [33], our mortality estimate would increase
to 10.6%, similar to pooled estimates reported from stud-
ies in sub-Saharan Africa [32]. Over time, recorded mor-
tality after ART initiation decreased substantially, with
individuals initiating ART in 2010–2011 having 60% lower
hazard of recorded death compared to individuals initiat-
ing ART in 2006–2007. This decrease was substantially
larger than the increase in LTF observed between the
same time periods, suggesting that differential ascertain-
ment of deaths does not explain the improvement in mor-
tality over time.
The strengths and weaknesses of this study both arise
from the data source. We used data routinely collected
Melaku et al. BMC Public Health  (2015) 15:462 Page 12 of 13as part of clinical HIV care in Ethiopia, rather than data
collected as part of a research study. Clinical data often
has more missing information than that collected as part
of a research study, as evidenced by the high levels of
missing data on CD4+ cell counts at enrollment in HIV
care. In addition, we relied on death recorded as part of
routine clinical care and did not independently verify
vital status. Additionally, a large proportion of patients
were classified as having a point of HIV testing at an-
other hospital or health center (14%) or had missing in-
formation on point of testing (17%). For these patients,
we are unable to ascertain whether the testing was
through PITC or VCT. However, utilization of routinely-
collected data has enabled us to report on a very large
population of individuals seeking HIV care in Ethiopia.
Our study population comprised 53,300 adults initiating
ART between 2006 and 2011 in Ethiopia. UNAIDS esti-
mates of the total number of individuals currently re-
ceiving ART in Ethiopia through the end of 2011 to be
approximately 265,000 [34], suggesting that approxi-
mately 20% of adults receiving ART in Ethiopia are in-
cluded in our study. Consequently, our assessment
provides a more representative sample of patients and
outcomes from the types of clinics where the majority of
HIV-positive individuals in Ethiopia are seeking HIV
care.
Conclusions
These Ethiopian health facilities have shown earlier iden-
tification and engagement in care of HIV-positive indi-
viduals over time across all points of HIV testing.
Patients at the HIV clinics included in this analysis were
enrolled in HIV services at higher median CD4+ cell
counts and lower WHO stage over time, and fewer pa-
tients initiated ART with advanced WHO stage. Pre-
ART retention, prompt initiation of eligible persons on
ART, and retention after ART initiation (particularly in
the first 6 months) remain major challenges.
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